Pancreatic Cancer Research

Clinical trialObservationalTerminated

Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

Outcome
Stopped earlyEnrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients. (Enrollment)
Phase
Observational
Status
Terminated
Study type
Observational
Start
22 December 2020
Ended
2 June 2025
Enrollment
112 participants
Sites
6
Primary outcomes
Disease-free survival (DFS)
Sponsor type
Academic / other
Results posted
No
Last update
17 November 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

PROJECTION is a non-randomized, multicenter, non-interventional cohort study in patients with resectable pancreatic ductal adenocarcinoma (PDAC). Patients are allocated to two observation groups according to the preoperative presence (Group A) or absence (Group B) of circulating tumor DNA (ctDNA) in a liquid biopsy analyzed with FoundationOne Liquid CDx. After surgery and completion of local histological evaluation, tumor tissue is analyzed with FoundationOne CDx. Earlier protocol versions also included a second liquid biopsy within 14 days before the start of adjuvant chemotherapy. Patients are followed for recurrence according to institutional standards about every three months for the first 18 months after surgery and about every six months thereafter, until recurrence or death, for a maximum of 36 months after surgery and until May 31, 2025 at the latest. Enrollment was stopped on May 31, 2024.